Zhejiang Orient Gene Biotech (688298.SH) announced a forecasted net loss of 485 million to 535 million yuan in 2024.

Zhejiang Orient Gene Biotech (688298. SH) announced that, according to preliminary calculations by the financial department, it is expected that the net profit attributable to the owners of the parent company in 2024 will show a loss compared to the previous year (statutory disclosed data of -398 million yuan), with a net profit attributable to the owners of the parent company of -485 million yuan to -535 million yuan. The net profit attributable to the owners of the parent company after deducting non-recurring gains and losses is expected to be -550 million yuan to -595 million yuan. In the current year, the company's operating performance mainly comes from routine testing business, which has maintained stable development overall. However, due to the impact of the economic environment and intense industry competition, some acquisitions and new projects have not achieved the expected short-term performance. The scale of performance before listing was relatively small, and the research and development, clinical trials, registration and certification, market promotion, and customer validation of key products currently require a certain time period.